MIRM
Mirum Pharmaceuticals, Inc.67.05
+2.95+4.6%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
3.47BP/E (TTM)
-Basic EPS (TTM)
-0.84Dividend Yield
0%Recent Filings
8-K
10-Q
Q3 FY2025 results
Mirum Pharmaceuticals swung to a $2.9M net profit in Q3 2025, fueled by $133.0M in product sales that surged 47.3% year-over-year (derived) from $90.3M, with Livmarli up 55.8% to $92.2M and Bile Acid Medicines climbing 30.8% to $40.8M, while gross margin held steady at 80.8% despite higher royalties. Operating income flipped to $2.6M from a $12.7M loss, driven by revenue momentum outpacing a 26.5% rise in expenses to $130.4M, including R&D for volixibat and MRM-3379 trials. Cash swelled to $378.0M, bolstered by $49.8M in operating cash flow, with $309.4M in convertible notes due 2029 at 4.0% and no revolver. The Bile Acid acquisition from Travere closed in August 2023 for $210.4M cash, adding $231.9M in intangibles amortized over 10.4 years. Yet competition from generics and other biotechs looms large.
8-K
Q3 revenue hits $133M
Mirum Pharmaceuticals reported third-quarter 2025 total revenue of $133 million, up from $90.4 million last year, driven by LIVMARLI sales surging 56% to $92.2 million and bile acid medicines growing 31% to $40.8 million. The company raised its full-year revenue guidance to $500–$510 million while advancing its pipeline, completing enrollment in the volixibat VISTAS PSC study with topline data due in Q2 2026. Cash reserves stand at $378 million. Momentum builds toward 2026 catalysts.
10-Q
Q2 FY2025 results
Mirum Pharmaceuticals posted solid Q2 FY2025 results, with product sales jumping 64% year-over-year to $127.8M, driven by Livmarli's $88.2M haul (up 87% y/y) and Bile Acid Medicines at $39.6M (up 30% y/y), while U.S. revenue swelled 47% y/y to $95.5M. Gross margins held steady around 82%, but operating expenses climbed 30% y/y to $132.8M on R&D for volixibat and MRM-3379 plus sales ramp-up, yielding a narrower operating loss of $5.0M versus $24.2M last year. Cash and equivalents hit $228.1M, with $321.7M in unrestricted liquidity funding ops into 2026; free cash flow stood at $10.1M YTD. Convertible notes of $309M mature 2029 at 4% effective rate, with Q3 conversion window open. Yet competition from generics and other IBAT inhibitors looms large.
8-K
Q2 revenue beats, guidance up
Mirum Pharmaceuticals reported Q2 2025 total revenue of $128 million, up from $78 million last year, driven by LIVMARLI net sales of $88.2 million—a 87% surge—and Bile Acid Medicines at $39.6 million, up 30%. The company raised its full-year revenue guidance to $490–$510 million, citing strong international growth and U.S. PFIC launch momentum. Pipeline advances include volixibat's VISTAS study completing enrollment this quarter, with PSC topline data in Q2 2026. Cash reserves hit $322 million.
ALNY
Alnylam Pharmaceuticals, Inc.
391.17-0.33
BMRN
BioMarin Pharmaceutical Inc.
51.77-0.35
GLMD
Galmed Pharmaceuticals Ltd.
0.98+0.01
LIANY
LianBio
0.09+0.00
LRMR
Larimar Therapeutics, Inc.
3.74-0.18
MREO
Mereo BioPharma Group plc
2.10-0.09
NMRA
Neumora Therapeutics, Inc.
1.85-0.11
PHAT
Phathom Pharmaceuticals, Inc.
15.24+0.55
VNDA
Vanda Pharmaceuticals Inc.
6.65+0.02
XFOR
X4 Pharmaceuticals, Inc.
3.71-0.05